17 completed, 5 unknown, 2 withdrawn, 1 not yet recruiting. 27 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 27 | Completed 17, Unknown 5, Withdrawn 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow Vortioxetine: new trials by email Literature Review of Vortioxetine trials Research Report on Vortioxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) Vortioxetine, Cariprazine (Augmentation Phase) - Unipolar Depression, Bipolar Depression | Phase 4 | Recruiting | Mayo Clinic | 120 | 2026-02-17 | 2026-06-22 |
| Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease Vortioxetine (tablet) - Parkinson Disease, Idiopathic, Freezing of Gait | Phase 4 | Not yet recruiting | Marianna Amboni | 40 | 2025-02-01 | 2025-02-06 |
| Vortioxetine Adjunctive Treatment in Bipolar Depression Vortioxetine, valprote - Bipolar Depression | Phase 4 | Completed | First Affiliated Hospital of Zhejiang University | 131 | 2022-03-01 | 2023-09-14 |
| MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users Vortioxetine - Relapse, Cognitive Impairment | Phase 4 | Unknown | Sir Run Run Shaw Hospital | 220 | 2020-09-01 | 2019-11-29 |
| Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression Vortioxetine, Desvenlafaxine - Major Depressive Disorder | Phase 4 | Completed | H. Lundbeck A/S | 605 | 2020-06-18 | 2022-02-14 |
| Vortioxetine in Patients With Depression and Early Dementia Vortioxetine - Major Depressive Disorder, Dementia | Phase 4 | Completed | H. Lundbeck A/S | 82 | 2020-02-28 | 2022-08-08 |
| Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India Vortioxetine - Major Depressive Disorder | Phase 4 | Completed | H. Lundbeck A/S | 400 | 2020-02-20 | 2022-03-18 |
| Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD) Vortioxetine - MDD, Anxiety Disorders | Phase 4 | Completed | H. Lundbeck A/S | 100 | 2019-12-27 | 2021-04-20 |
| Tolerability, Safety and Efficacy of Vortioxetine Vortioxetine - Depression | Phase 4 | Unknown | IRCCS San Raffaele Roma | 20 | 2019-11-20 | 2023-06-22 |
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes Vortioxetine - Type2 Diabetes, Major Depressive Disorder | Phase 4 | Withdrawn | Todd Doyle | 2019-07-01 | 2022-11-29 | |
| Study With Vortioxetine on Emotional Functioning in Patients With Depression Vortioxetine - Major Depressive Disorder | Phase 4 | Completed | H. Lundbeck A/S | 150 | 2019-02-05 | 2020-03-24 |
| Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment Vortioxetine, Sertraline, citalopram - Major Depressive Disorder | Phase 4 | Completed | Azienda Ospedaliera Universitaria Integrata Verona | 362 | 2019-02-01 | 2023-05-19 |
| Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine Vortioxetine - Depressive Disorder, Major Depression | Phase 4 | Terminated | Massachusetts General Hospital | 2 | 2017-08-24 | 2019-10-14 |
| Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder Vortioxetine - Major Depressive Disorder | Phase 4 | Completed | Takeda | 123 | 2016-12-22 | 2019-07-11 |
| Vortioxetine for Posttraumatic Stress Disorder Placebo, Vortioxetine - Post-Traumatic Stress Disorder | Phase 4 | Completed | University of Miami | 41 | 2016-12-01 | 2021-02-08 |
| The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder vortioxetine - Major Depressive Disorder | Phase 4 | Completed | Rush University Medical Center | 31 | 2016-12-01 | 2021-10-04 |
| Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers Vortioxetine, Paroxetine, Placebo - Healthy Volunteers | Phase 4 | Completed | Takeda | 361 | 2016-11-21 | 2018-09-14 |
| Cognitive Dysfunction in MDD Patients Vortioxetine, Escitalopram - Major Depressive Disorder | Phase 4 | Unknown | Oleg Levada | 150 | 2016-10-01 | 2019-01-10 |
| Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training Vortioxetine 10 mg, Cognitive training program - Age-related Cognitive Decline | Phase 4 | Completed | Washington University School of Medicine | 129 | 2016-08-31 | 2020-01-14 |
| Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers Vortioxetine - Unipolar Major Depression, Stage I, II or III Breast Cancer | Phase 4 | Withdrawn | University of Miami | 2016-07-01 | 2016-09-30 |
Showing 20 of 27. Sign in to see all of them.
Depressive Disorder, Major (13) · Depression (10) · Anxiety Disorders (2) · Bipolar Disorder (2) · Cognitive Dysfunction (2) · Depressive Disorder (2) · Diabetes Mellitus, Type 2 (2) · Parkinson Disease (2) · Dementia (1) · Hot Flashes (1) · Neurobehavioral Manifestations (1) · Panic Disorder (1) · Phobia, Social (1) · Recurrence (1) · Schizophrenia (1)
H. Lundbeck A/S (5) · Takeda (3) · Massachusetts General Hospital (2) · University of Miami (2) · Azienda Ospedaliera Universitaria Integrata Verona (1) · First Affiliated Hospital of Zhejiang University (1) · IRCCS San Raffaele Roma (1) · Lundbeck Canada Inc. (1) · Marianna Amboni (1) · Mayo Clinic (1) · Northwell Health (1) · Oleg Levada (1) · Rush University Medical Center (1) · Sir Run Run Shaw Hospital (1) · Siyan Clinical Corporation (1)
United States (13) · Italy (5) · Spain (4) · Estonia (3) · France (3) · Poland (2) · South Korea (2) · Ukraine (2) · Argentina (1) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · India (1)
Andrew Nierenberg, M.D. (1) · Aysegul Ozerdem, MD, PhD (1) · Christoph U Correll, MD (1) · Deniz Ceylan, MD, PhD (1) · Dominique Musselman, M.D., MSCR (1) · Eric Lenze, MD (1) · Isela Juarez Rojop, Ph.D (1) · John M Zajecka, MD (1) · Li YouMing (1) · Marlene P Freeman, MD (1) · Michael R Liebowitz, M.D. (1) · Philip Harvey, PhD (1) · Pratap Chokka, M.D. (1)
PMID 29760763, PMID 30802419, PMID 31930057, PMID 32212856, PMID 32384884, PMID 32746941, PMID 33587394, PMID 34378539, PMID 34895181, PMID 35131363, PMID 35499104, PMID 36395989, PMID 37227402, PMID 37315590, PMID 38384338, PMID 38869978, PMID 39110846, PMID 40456468, PMID 40679716
2018 (2), 2016 (1)